2023-08-04 07:12:10 ET
- Fulgent Genetics press release ( NASDAQ: FLGT ): Q2 Non-GAAP EPS of -$0.08 beats by $0.25 .
- Revenue of $67.85M (-45.9% Y/Y) beats by $5.37M .
- Adjusted EBITDA loss of $2.7 million.
- Generated cash flow from operations of $9.7 million.
- Cash, cash equivalents, and investments in marketable securities of $846.8 million as of June 30, 2023.
- Raises Full Year 2023 Core Revenue Guidance to $260 million and Narrows Expected Loss.
- Outlook: For the third quarter of 2023 , Fulgent expects: Core Revenue of approximately $65 million vs. consensus of $62.84M.
-
For the full year 2023 , Fulgent now expects: Core Revenue of approximately $260 million vs. consensus of $255.94M; GAAP loss of approximately $2.15 per share; Non-GAAP loss of approximately $0.95 per share vs. consensus of -$1.23.
For further details see:
Fulgent Genetics beats Q2 top and bottom line estimates; initiates Q3 and updates FY23 outlook